Gilead SciencesGILD
Recorded

Gilead Sciences 8th Annual Wolfe Research Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration28 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Alexandria HammondAnalyst

Good morning, everybody. My name is Alex Hammond, and I am the biopharma analyst here at Wolfe, and today it is my pleasure to host Gilead Sciences. We have Cindy Perettie, who is EVP of Kite, a Gilead Company. With that, Cindy, thank you so much for joining us.

Cindy PerettieEVP of Kite

Very nice to be here.

Alexandria HammondAnalyst

Obviously, it is a really exciting time for Gilead on the cell therapy front. I think it would make sense to maybe kind of take a step back and think about what you have learned from Yescarta and Tecartus, and what you have been doing boots on the ground that is going to further kind of help the anito-cel launch.

Cindy PerettieEVP of Kite

Thanks for that, Alex. The piece that Yescarta and Tecartus have allowed us to do is set the foundation. Cell therapy is not a typical delivery model, so you need to build up a number of aspects. One is your authorized treatment center footprint. Today, at launch for anito-cel, we will have 200 authorized treatment centers in the U.S. If you think about launches that may have occurred prior to this, they would have had 30 or 40 authorized treatment centers, and that was similar to when we came with Yescarta and Tecartus. The second piece is our ability to manufacture the product, and that is no small feat as well. We have had the opportunity over the last decade to really build out our manufacturing capacity, as well as integrating vector capacity.

Cindy PerettieEVP of Kite

Anito-cel, we are now producing in-house, and we are looking forward to, as we come to launch, to be able to provide the same experience that lymphoma physicians receive from Kite on the myeloma space. What does that look like? We have today turnaround times between two and three weeks with our commercial products. We expect to have the same as we come to launch with anito-cel. We have 97% reliability on Yescarta and Tecartus. We published at ASCO this summer that we have 99% on anito-cel. That will change, obviously, as we continue to get more volume. But having the reliability, the rapid turnaround times, is something that is an opportunity for many of these centers who have not experienced it with the existing products, where turnaround times could be over a month, out-of-spec rates at 20%.

Cindy PerettieEVP of Kite

We are excited to build off of what we have done with Yescarta and Tecartus, the relationships we have built in these centers with the hematology divisions, and bring anito-cel.

Alexandria HammondAnalyst

I guess with that, I would love to hear your thoughts on moving from purely an academic center to a community center with some of the reduction of the REMS, and how important will that be to anito-cel?

Cindy PerettieEVP of Kite

It is really important. You can imagine the community is incredibly important to us. Today, 80% of cancer patients are diagnosed in the community. 80%. 80% of them are being seen in the community. Moving into the community is increasingly important. We will be launching anito-cel in the fourth line plus indication, and today, many of those patients are actually in academic centers. Our existing footprint we have today, the 200 centers, a majority of them are academic centers, but we have about 25 community practices, and we continue to build on that every year. But for the fourth line launch, we know that the authorized treatment centers that are academic are going to be where most of those patients are.

Cindy PerettieEVP of Kite

When we come out with our iMMagine-3 data in the second line plus, the community becomes incredibly important, and that's why you're seeing the efforts we're taking today to move into the community. The safety profile of anito-cel lends itself very nicely to be delivered in the outpatient setting and in the community, and so physicians are now going to get experience with that.

Alexandria HammondAnalyst

As you move into earlier lines, patients are also fitter, and therefore the safety profile is even- That's exactly right.

Cindy PerettieEVP of Kite

You raised the point about the REMS. That can't be underestimated. When many of these products launched, including Yescarta and Tecartus, there was a REMS program, and that also can be difficult for patients to not be treated close to home. So the ability to reach patients in the community where they are is really important.

Alexandria HammondAnalyst

I guess as well, you mentioned the 200 active treatment sites as well. We have the lack of REMS. What do you kind of see as the hurdles or the barriers to the first year of launch? Because obviously more of a 2027 than a 2026 launch.

Cindy PerettieEVP of Kite

It is. Coming in as early Christmas gift. The things that were barriers in the past, you talked about the REMS program, that was definitely a barrier with the regulatory agencies in the past. The other piece, when CAR-Ts first came out, were that there weren't slots, right? So slot availability was an issue, so every patient maybe wasn't going to be able to get cell therapy, or physicians and patients had to wait for a slot to open. That's no longer the case. The capacity we have with our manufacturing today can serve Yescarta, Tecartus, and anito-cel well beyond the launch in fourth line, and certainly coming into earlier lines. So we feel very confident about some of those things that were hurdles in the past will not be hurdles in the future.

Alexandria HammondAnalyst

As we think about the label as well for anito-cel, I think PDUFA is what, December 23rd?

Alexandria HammondAnalyst

That's right. Anything that we as investors and the sell side should be looking out for that will be particularly important to kind of help with the launch?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day